JP2018528236A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528236A5
JP2018528236A5 JP2018515561A JP2018515561A JP2018528236A5 JP 2018528236 A5 JP2018528236 A5 JP 2018528236A5 JP 2018515561 A JP2018515561 A JP 2018515561A JP 2018515561 A JP2018515561 A JP 2018515561A JP 2018528236 A5 JP2018528236 A5 JP 2018528236A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
salt
diastereomer
enantiomer
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018515561A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528236A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/052442 external-priority patent/WO2017053222A1/en
Publication of JP2018528236A publication Critical patent/JP2018528236A/ja
Publication of JP2018528236A5 publication Critical patent/JP2018528236A5/ja
Priority to JP2021169263A priority Critical patent/JP7332666B2/ja
Priority to JP2023130574A priority patent/JP7573078B2/ja
Withdrawn legal-status Critical Current

Links

JP2018515561A 2015-09-24 2016-09-19 真皮障害を治療または予防するための新規組成物および方法 Withdrawn JP2018528236A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021169263A JP7332666B2 (ja) 2015-09-24 2021-10-15 真皮障害を治療または予防するための新規組成物および方法
JP2023130574A JP7573078B2 (ja) 2015-09-24 2023-08-10 真皮障害を治療または予防するための新規組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562232228P 2015-09-24 2015-09-24
US62/232,228 2015-09-24
PCT/US2016/052442 WO2017053222A1 (en) 2015-09-24 2016-09-19 Novel compositions and methods for treating or preventing dermal disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021169263A Division JP7332666B2 (ja) 2015-09-24 2021-10-15 真皮障害を治療または予防するための新規組成物および方法

Publications (2)

Publication Number Publication Date
JP2018528236A JP2018528236A (ja) 2018-09-27
JP2018528236A5 true JP2018528236A5 (cg-RX-API-DMAC7.html) 2019-10-31

Family

ID=58387119

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018515561A Withdrawn JP2018528236A (ja) 2015-09-24 2016-09-19 真皮障害を治療または予防するための新規組成物および方法
JP2021169263A Active JP7332666B2 (ja) 2015-09-24 2021-10-15 真皮障害を治療または予防するための新規組成物および方法
JP2023130574A Active JP7573078B2 (ja) 2015-09-24 2023-08-10 真皮障害を治療または予防するための新規組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021169263A Active JP7332666B2 (ja) 2015-09-24 2021-10-15 真皮障害を治療または予防するための新規組成物および方法
JP2023130574A Active JP7573078B2 (ja) 2015-09-24 2023-08-10 真皮障害を治療または予防するための新規組成物および方法

Country Status (9)

Country Link
US (4) US10695326B2 (cg-RX-API-DMAC7.html)
EP (2) EP3352755B1 (cg-RX-API-DMAC7.html)
JP (3) JP2018528236A (cg-RX-API-DMAC7.html)
KR (1) KR20180081501A (cg-RX-API-DMAC7.html)
CN (2) CN108348508A (cg-RX-API-DMAC7.html)
AU (1) AU2016325446B2 (cg-RX-API-DMAC7.html)
CA (1) CA3037469C (cg-RX-API-DMAC7.html)
ES (1) ES3060762T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017053222A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
WO2017053222A1 (en) * 2015-09-24 2017-03-30 Drexel University Novel compositions and methods for treating or preventing dermal disorders
US20190167649A1 (en) * 2016-08-10 2019-06-06 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
EP3863606A4 (en) * 2018-10-11 2022-07-20 Drexel University METHODS OF TREATMENT OR PREVENTION OF SKIN DISEASES
JP7516252B2 (ja) * 2018-11-02 2024-07-16 株式会社 資生堂 オルタナティブオートファジー誘導剤を含む紫外線起因性炎症抑制剤
KR102132921B1 (ko) * 2018-12-13 2020-07-13 영남대학교 산학협력단 조타로리무스를 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물
AU2020277132B1 (en) 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US20040180430A1 (en) 1999-09-07 2004-09-16 West Michael D. Methods of restoring telomere length and extending cell lifespan using nuclear transfer
US7026374B2 (en) 2002-06-25 2006-04-11 Aruna Nathan Injectable microdispersions for medical applications
EP1646635A1 (en) 2003-07-16 2006-04-19 Wyeth Cci-779 isomer c
US20050250805A1 (en) * 2004-05-06 2005-11-10 Glenmark Pharmaceuticals Limited Pharmaceutical ointment formulations
KR20070121746A (ko) 2005-03-14 2007-12-27 매크로켐 코포레이션 사람 피부를 통한 마크롤라이드 침투의 개선
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
MXPA06008797A (es) * 2006-08-03 2008-02-04 Fernando Ahumada Ayala Preparacion topica para el tratamiento de enfermedades inflamatorias de la piel que contiene sirolimus.
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
EP2155146A4 (en) 2007-05-15 2012-11-21 Puretech Ventures METHOD AND COMPOSITIONS FOR TREATING SKIN TREATMENTS
WO2009046436A1 (en) * 2007-10-04 2009-04-09 Memorial Sloan-Kettering Cancer Center Methods for inhibiting senescence of epithelial cells
WO2010056778A1 (en) * 2008-11-11 2010-05-20 Signum Biosciences, Inc. Isoprenyl compounds and methods thereof
AU2013204219B2 (en) * 2009-04-10 2015-05-07 Haiyan Qi Novel anti-aging agents and methods to identify them
WO2010118419A2 (en) * 2009-04-10 2010-10-14 Haiyan Qi Novel anti-aging agents and methods to identify them
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
WO2011079154A1 (en) * 2009-12-21 2011-06-30 Sarah Bacus Compositions and methods for treatment of vitiligo
JP5652795B2 (ja) * 2011-01-31 2015-01-14 国立大学法人大阪大学 皮膚疾患を処置するための外用薬およびその製造方法
WO2012142145A1 (en) 2011-04-12 2012-10-18 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
CN104080786A (zh) * 2011-11-08 2014-10-01 因特利凯有限责任公司 使用多种药剂的治疗方案
WO2014004692A1 (en) 2012-06-26 2014-01-03 Sarah Bacus Compositions and methods for treatment vitiligo
US9296733B2 (en) * 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
EA201690987A1 (ru) * 2013-11-13 2016-10-31 Новартис Аг Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
US9980976B2 (en) * 2015-02-17 2018-05-29 Northwestern University Use of REDD1 inhibitors to dissociate therapeutic and adverse atrophogenic effects of glucocorticoid receptor agonists
WO2017053222A1 (en) 2015-09-24 2017-03-30 Drexel University Novel compositions and methods for treating or preventing dermal disorders

Similar Documents

Publication Publication Date Title
CL2023001738A1 (es) Inhibidores de prmt5
CL2023000921A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead
JOP20230277A1 (ar) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز (pi3k) لعلاج الأمراض
Li et al. Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones
FR2887886B1 (fr) Polymere cationique neutralise, composition le comprenant et procede de traitement cosmetique
AR088730A1 (es) Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
WO2017127430A8 (en) Irak4 inhibiting agents
IL248745B (en) (s)-2-amino-3-methyl butyric acid (r2, r3, rb11)-3 azazobutyl-9,10-dimethoxy-1,3,4,6,711b-hexahydro-h2-pyrido[a-1,2 ] isoquinoline-2-yl ester for use in the treatment of Tardib Discenza
NZ702357A (en) 5,6-benzoflavone compositions for treating and/or preventing skin disease associated with hyperseborrhea
NO20074697L (no) Ikke-aromatisk, nitrogenholdig heterosyklisk-1-karboksylatester-pyridylderivat
WO2011113802A3 (en) Imidazopyridine and purine compounds, compositions and methods of use
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
MX2009010407A (es) Derivados fluorados de deferiprona.
CY1113784T1 (el) Φαρμακευτικη συνθεση για την θεραπεια διαβητικων επιπλοκων
KR20180081501A (ko) 진피 장애를 치료하거나 예방하는 신규한 조성물 및 방법
WO2010017609A8 (en) Antiperspirant compositions and methods for reducing perspiration in humans
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
AR080871A1 (es) Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa
NZ608375A (en) Pharmaceutical combination of an mtor catalytic inhibitor and an allosteric mtor inhibitor
MX2022014290A (es) Inhibidor de vcp/p97 para tratamiento de cancer.
FR3029777B1 (fr) Utilisation de l'association d'un polyether polyurethane non-ionique associatif et d'un derive de cyclohexanol comme agent rafraichissant de la peau
Zuckermann et al. Sirolimus conversion after heart transplant: risk factors for acute rejection and predictors of renal function response
EP4183264A4 (en) COMPOSITION FOR THE TREATMENT OF BRAIN DISEASES WITH PEDIOCOCCUS INOPINATUS OR EXTRACELLULAR VESICLES THEREOF AS ACTIVE INGREDIENT
BR112021025618A2 (pt) Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto
UA87312C2 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ